Hong Kong Economic and Trade Office, USA
Hong Kong
News Release



ACT Genomics opens laboratory in Hong Kong to tap Greater Bay Area opportunities

 

 



For more information, please contact

Wing Yan Tong in San Francisco: (415) 835 9315

Melissa Ng in New York City: (212) 752 3320

Daniel McAtee in Washington, D.C.: (202) 238 6360




July 5, 2019 - ACT Genomics Holdings Co Ltd, a precision cancer treatment solution provider, has opened its Next Generation Sequencing (NGS) laboratory in Hong Kong as part of its strategic plan to meet growing demand for cancer genomic profiling services in the Guangdong-Hong Kong-Macao Greater Bay Area.

The new laboratory is located at the Hong Kong Science Park. Measuring about 7 000 square feet, the laboratory is supported by a workforce responsible for sales, medical science and research and laboratory work, and is equipped with dual sequencing platforms (Ion GeneStudio S5 System and NextSeq 550 System) that boast both speed (quick turnover time for clinical reports) and throughput (high specimen volume or high sequencing depth for research purposes). It is designed and built to serve the clinical, pharmaceutical and research communities in the city and Asia, and also aspires to capture the tremendous opportunities in the Greater Bay Area in future.

Founded in Taiwan in 2014, ACT Genomics provides cancer patients with personalised genomic information based-treatment plans through its cutting-edge NGS platform, medical reports and integrated services. The platform is capable of detecting multiple genomic alterations using a single tissue sample within a single test run.

When used together with sophisticated bioinformatics analysis tools, curated proprietary medical informatic databases and data visualisation technologies, it can match identified mutations with not only approved therapies but also targeted therapies in clinical trials, thereby facilitating "precision medicine" treatment.

At the ceremony on July 4, the Chief Executive Officer of ACT Genomics, Dr. Chen Hua-chien, said, "With over 31 000 new cancer cases in Hong Kong every year, it is crucial for cancer treatment solutions to stay on the cutting edge, which is the mission of ACT Genomics. We are here to transform the existing cancer treatment model and make cancer more manageable. Our NGS platform provides physicians with an essential reference for prescribing the most appropriate and effective treatment to a patient. We intend to draw from our successful experience in Taiwan and replicate it in Hong Kong with the help of this new world-class NGS laboratory."

Associate Director-General of Investment Promotion at Invest Hong Kong, Mr. Charles Ng, said, "Biotech is one of the innovation areas that is growing rapidly in Hong Kong. The Greater Bay Area is a huge market with a population of 71 million people. As the city is being positioned as the global innovation and technology hub within the Greater Bay Area and with our established business and legal systems, Hong Kong offers a convenient platform for international biotech and other laboratories to manage their operations across the Greater Bay Area."

2019 © | Important notices       Privacy policy      Accessibility                                                                                                                                                    Last Revision Date: July 5, 2019

 

Web For All W3C Web Accessibility initiative    
This website adopts web accessibility design and conforms to the World Wide Web Consortium (W3C) Web Content Accessibility Guidelines (WCAG) 2.0 Level AA standard. Should you have any enquiries or comments on its accessibility, please contact us by phone or email.